Financing led by Canaan and New Leaf Venture Partners, and includes funds managed by abrdn Inc., Correlation Ventures, and Mayo Clinic Ventures DEDHAM, Mass. — April 30, 2024 — Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round. […]
Archives for lrykardQlaris Bio’s Novel IOP-Lowering Product, QLS-111, Is Dosed In Phase II Trials
A first-in-class product, QLS‑111 is designed to lower intraocular pressure (IOP) beyond currently achievable levels in patients with glaucoma by targeting episcleral venous pressure (EVP) DEDHAM, Mass. — April 2, 2024 — Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate […]
An Interview With Dr. Shan Lin – Unmet Needs in Glaucoma & New Treatments On The Horizon
Please click below for an interview with Dr. Shan Lin, co-research director of the Glaucoma Center of San Francisco and a member of the Scientific Advisory Board of Qlaris Bio – Interviewed by Carey Powers of Powers & Company at the Glaucoma 360 New Horizons Forum 2024. https://vimeo.com/929695079